Germline mutations in BRCA1/2 (gBRCAMUT) are frequently identified in TNBC patients, ranging from 11–20% [3,4,5,6], in comparison to 5–7% [7,8,9] of all breast cancers. This evidence concerns the gene BRCA1 and breast carcinoma.